Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
3.210
-0.090 (-2.73%)
At close: Oct 26, 2026, 4:00 PM EDT
3.370
+0.160 (4.98%)
After-hours: Oct 26, 2026, 4:27 PM EDT
Camp4 Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Camp4 Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $10.22. The average 1-year stock price forecast is 218.38% higher than the current stock price, while the lowest is $6.00 (+86.92%) and the highest is $15 (+367.29%).
Price Target: $10.22 (+218.38%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Camp4 Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 7 |
| Buy | 1 | 2 | 2 | 2 | 2 | 3 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 7 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Buy Initiates $8 | Buy | Initiates | $8 | +149.22% | Oct 16, 2026 |
| Wedbush | Wedbush | Buy Maintains $8 | Buy | Maintains | $8 | +149.22% | Sep 29, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $15 | Buy | Reiterates | $15 | +367.29% | Sep 29, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $6.5 → $6 | Buy | Reiterates | $6.5 → $6 | +86.92% | Sep 29, 2026 |
| William Blair | William Blair | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 29, 2026 |
Financial Forecast
Revenue This Year
6.03M
from 3.50M
Increased by 72.44%
Revenue Next Year
4.39M
from 6.03M
Decreased by -27.24%
EPS This Year
-1.13
from -1.65
EPS Next Year
-0.85
from -1.13
EPS and Forward PE are based on non-GAAP adjusted numbers.